정확한 분자진단 및 표적 치료에 대한 수요가 지속적으로 증가함에 따라 맞춤형 의료에 대한 수요 증가가 핵산 분리 및 정제 시장의 주요 촉진제가 될 것으로 예상되며, Verified Market Research의 애널리스트에 따르면, 핵산 분리 및 정제 시장은 2024년 약 48억 8,000만 달러로 예측 기간 동안 87억 8,000만 달러의 가치에 도달할 것으로 추정됩니다.
핵산 분리 및 정제 시장의 급격한 확대는 주로 생명공학 및 유전체학의 발전의 확대에 힘입어 시장의 CAGR을 크게 끌어올릴 것으로 예상됩니다. 이에 따라 시장은 2024년부터 2031년까지 8.40%의 CAGR로 성장할 것으로 예상됩니다.
핵산 분리 및 정제 시장 정의/개요
핵산 분리 및 정제는 분자생물학에서 중요한 과정으로, 생물학적 샘플에서 DNA, RNA 및 기타 핵산을 추출 및 정제하도록 설계되었습니다. 이러한 과정은 유전자 연구, 진단, 치료법 개발 등 다양한 용도에 필수적입니다. 핵산 분리 및 정제에 사용되는 기술은 원심분리, 여과, 마그네틱 비드를 이용한 접근법 등 다양합니다. 이러한 공정에서 얻어진 핵산의 품질과 무결성은 후속 분석 및 응용에 매우 중요합니다.
생명공학 및 유전체학의 발전으로 인해 핵산 분리 및 정제 시장이 크게 성장하고 있습니다. 맞춤형 의료에 대한 수요 증가와 고처리량 시퀀싱 기술의 발전은 이 시장의 성장에 기여할 것으로 예상됩니다. 연구와 임상 응용이 계속 발전함에 따라 효율적이고 신뢰할 수 있는 핵산 분리 및 정제 방법에 대한 필요성이 증가하여 전체 시장의 성장을 뒷받침할 것으로 예상됩니다.
핵산 분리 및 정제 시장의 확대는 차세대 시퀀싱(NGS) 기술의 채택이 증가함에 따라 크게 촉진되고 있으며, NGS 기술은 유전자 연구, 맞춤 의료, 종양학 등 다양한 용도에 필수적인 고처리량 시퀀싱 기능을 제공함으로써 유전체 연구에 혁명을 일으켰습니다. Verified Market Research에 따르면, 차세대 시퀀싱(NGS) 시장 규모는 2024년 88억 7,000만 달러로 평가되었으며, 2024년부터 2031년까지 예측 기간 동안 CAGR 20.39%로 2031년에는 391억 5,000만 달러에 달할 것으로 예상됩니다.
고품질 핵산 샘플에 대한 수요는 정밀하고 정확한 시퀀싱 결과에 대한 필요성에 의해 촉진되고 있으며, 이는 핵산 분리 및 정제 제품 시장을 더욱 촉진할 것으로 예상됩니다. 그 결과, 분리 및 정제 기술의 발전은 NGS의 효율성과 효과를 높여 시장 성장의 확대로 이어질 것으로 예상됩니다.
핵산 분리 및 정제 시장은 고급 분리 및 정제 장비의 높은 비용으로 인해 큰 제약에 직면해 있습니다. 정교한 기술과 시약에 필요한 초기 투자비용은 많은 실험실, 특히 개발도상국의 실험실에서는 감당하기 어려운 수준입니다.
예를 들어, 자동 액체 취급 플랫폼이나 고처리량 정제기와 같은 고급 시스템은 10만 달러 이상의 비용이 소요될 수 있으며, 이로 인해 접근성 및 채택이 제한되고 있습니다. 이러한 높은 비용은 특히 예산 제약이 많은 지역에서는 시장 성장을 저해할 것으로 예상됩니다. 핵산 분리 및 정제 제품 세계 시장은 자금 조달이 어려운 지역에서는 성장률이 둔화될 것으로 추정됩니다. 이처럼 장비 및 시약의 높은 비용이 시장 확대의 큰 장벽이 되어 전체 산업의 성장 궤도에 영향을 미칠 것으로 예상됩니다.
Increasing demand for personalized medicine is expected to be a key driver in the nucleic acid isolation and purification market, as the need for precise molecular diagnostics and targeted therapies continues to grow. According to the analyst from Verified Market Research, the Nucleic Acid Isolation And Purification Market is estimated to reach a valuation of USD 8.78 Billion over the forecast subjugating around USD 4.88 Billion valued in 2024.
The rapid expansion of the nucleic acid isolation and purification market is primarily driven by the growing advancements in biotechnology and genomics, which are anticipated to significantly boost the CAGR of the market. It enables the market to grow at aCAGR of 8.40% from 2024 to 2031.
Nucleic Acid Isolation And Purification Market: Definition/ Overview
Nucleic acid isolation and purification are critical processes in molecular biology, designed to extract and purify DNA, RNA, or other nucleic acids from biological samples. These processes are essential for a range of applications, including genetic research, diagnostics, and therapeutic development. Techniques employed in nucleic acid isolation and purification are varied and include methods such as centrifugation, filtration, and magnetic bead-based approaches. The quality and integrity of nucleic acids obtained through these processes are crucial for subsequent analysis and applications.
Increasing advancements in biotechnology and genomics are driving significant growth in the nucleic acid isolation and purification market. The rising demand for personalized medicine and advancements in high-throughput sequencing technologies are expected to contribute to this market's expansion. As research and clinical applications continue to evolve, the necessity for efficient and reliable nucleic acid isolation and purification methods is projected to increase, supporting the overall market growth.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The expansion of the nucleic acid isolation and purification market is being significantly driven by the increasing adoption of next-generation sequencing (NGS) technologies. NGS technologies have revolutionized genomic research by providing high-throughput sequencing capabilities, which are essential for a variety of applications, including genetic research, personalized medicine, and oncology. According the Verified Market Research, the next-generation sequencing (NGS) market size was valued to be USD 8.87 Billion in the year 2024 and it is expected to reach USD 39.15 Billion in 2031, at a CAGR of 20.39% over the forecast period of 2024 to 2031.
The demand for high-quality nucleic acid samples is being propelled by the need for precise and accurate sequencing results, which is expected to further boost the market for nucleic acid isolation and purification products. Consequently, advancements in isolation and purification technologies are being anticipated to enhance the efficiency and effectiveness of NGS, leading to increased market growth.
The nucleic acid isolation and purification market faces significant constraints due to the high cost of advanced isolation and purification equipment. The initial investment required for sophisticated technologies and reagents can be prohibitive for many laboratories, particularly those in developing regions.
For instance, advanced systems such as automated liquid handling platforms and high-throughput purifiers can cost upwards of $100,000, which limits their accessibility and adoption. This high cost is projected to restrain market growth, particularly in regions where budget constraints are prevalent. It is estimated that the global market for nucleic acid isolation and purification products will experience slower growth rates in regions with less funding availability. Thus, the high cost of equipment and reagents is expected to be a significant barrier to market expansion, impacting the overall growth trajectory of the industry.
According to VMR analyst, pharmaceutical and biotechnology companies are expected to dominate as the leading end-user segment. This dominance is attributed to the extensive use of nucleic acid isolation and purification techniques in drug discovery, development, and personalized medicine. It is anticipated that these companies will continue to drive demand due to their need for high-quality nucleic acid samples for genetic research, biomarker discovery, and therapeutic development.
The pharmaceutical and biotechnology sector is projected to account for the largest share of the market, driven by the increasing number of drug development projects and rising investments in biotechnology research.
In the nucleic acid isolation and purification market, RNA isolation is projected to experience rapid growth compared to other nucleic acid types. This growth is largely driven by the rising prevalence of RNA-based therapies and the increasing use of RNA in molecular diagnostics and research.
The growing interest in RNA sequencing and the development of RNA-targeted treatments are anticipated to fuel demand for RNA isolation products. The RNA isolation segment is expected to witness a significant increase in market share, driven by advancements in RNA extraction technologies and the expanding applications of RNA in personalized medicine.
According to VMR Analyst, in North America, the nucleic acid isolation and purification market is expected to experience substantial growth, driven by several key factors. The region's advanced healthcare infrastructure, significant investments in research and development, and high concentration of leading pharmaceutical and biotechnology companies are anticipated to contribute to its dominance.
The U.S. government allocated over USD 3.8 Billion to the
Human Genome Project
between 1990 and 2003, with funding provided by the National Institutes of Health (NIH) and the Department of Energy (DOE). Additionally, the NIH's "All of Us" Research Program has been granted USD 1.5 Billion over ten years starting from 2016. This initiative aims to enhance precision medicine by gathering comprehensive health data from a diverse population to better understand the impact of individual differences on health and treatment.
Additionally, the strong presence of academic research institutes and diagnostic centers in North America is likely to further support market expansion. The increasing adoption of next-generation sequencing (NGS) technologies and rising demand for personalized medicine are projected to drive the need for efficient nucleic acid isolation and purification solutions.
In Asia Pacific, the nucleic acid isolation and purification market is projected to grow rapidly due to increasing investments in healthcare infrastructure and expanding research activities. The region's growing emphasis on biotechnology and genomics research, coupled with rising government funding for scientific research, is anticipated to drive market growth.
The increasing prevalence of chronic diseases and the expansion of diagnostic services are also expected to contribute to the demand for nucleic acid isolation and purification products. Moreover, the rise of local pharmaceutical and biotechnology companies and contract research organizations (CROs) is likely to further accelerate market expansion.
In 2020, Asia accounted for approximately 49.3% of global cancer cases, with around 9.5 million new diagnoses reported. However, the region's share of cancer-related deaths was notably higher, representing about 58.3% of the global total, translating to approximately 5.8 million fatalities. These statistics highlight Asia's significant burden of cancer, reflecting both the high incidence and mortality rates within the region.
The Nucleic Acid Isolation And Purification Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.
Some of the prominent players operating in the nucleic acid isolation and purification market include:
Agilent Technologies, Inc.
Beckman Coulter Life Sciences
Bio-Rad Laboratories, Inc.
GE Healthcare
Luminex Corporation
Merck KGaA
Promega Corporation
QIAGEN N.V.
Roche Diagnostics
Thermo Fisher Scientific, Inc.
In December 2023, Thermo Fisher Scientific Inc. introduced two new products: the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument, and the Applied Biosystems MagMAX Dx Pathogen/Viral NA Isolation Kit. These innovations are designed to enhance the isolation and purification of bacterial and viral pathogens from biological samples.
In November 2023, LGC Biosearch Technologies announced the acquisition of PolyDesign, a company specializing in solid support embedded frits used for DNA and RNA oligonucleotide synthesis and purification. This technology complements LGC's Nucleic Acid Chemistry product range.
In August 2023, CD Bioparticles introduced a new series of DNA Extraction and Purification Kits. These kits are designed for efficient and rapid isolation of various DNA types, including plasmid, genomic, cell-free (cfDNA), mitochondrial, tissue DNA, and PCR products.
In July 2023, INOVIQ Limited and Promega Corporation revealed a global marketing collaboration to promote Promega's Nucleic Acid purification systems and EXO-NET exosome capture technology.
In February 2023, Agilent Technologies, Inc. selected Fluor Corporation's Advanced Technologies & Life Sciences division to expand its oligonucleotide therapeutics manufacturing facility in Colorado, enhancing capabilities for synthesizing, lyophilizing, and purifying custom nucleic acid therapeutics.
In January 2023, QIAGEN launched the EZ2 Connect MDx platform, an automated solution for diagnostic labs that streamlines the purification of DNA and RNA from up to 24 samples in under 30 minutes.